person · Reporting owner
Minai-Azary Jennifer Lynn
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Context Therapeutics Inc.CNTX · Entity 7406 | Chief Financial Officer | February 19, 2026 | February 23, 2026 |
| Tempest Therapeutics, Inc.MLND · Entity 7734 | Chief Financial Officer | February 26, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Context Therapeutics Inc.
Report date February 19, 2026 · Filed February 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2036-02-18 | Direct | 275,000 |
Reported balance
After 2026-02-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-19 · Grant · Acquired 275,000 · Balance 275,000 F1: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.
Tempest Therapeutics, Inc.
Report date February 26, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.06 · Expires 2031-02-25 | Direct | 110,000 |
Reported balance
After 2021-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-26 · Grant · Acquired 110,000 · Balance 110,000 F1: 1. Twenty-five percent (25%) of the shares subject to this option shall vest on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. Twenty-five percent (25%) of the shares subject to this option shall vest on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2026 Filed Feb 23, 2026 16:21 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001628280-26-010642 · wk-form4_1771881698.xml · derivative · entry 1 Minai-Azary Jennifer Lynn · CIK 0001844398 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2036-02-18 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 17:22 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 40,010 | $0.64 | $25,486.37 |
DisclosureSEC source: 0001842952-25-000060 · wk-form4_1749590535.xml · nonDerivative · entry 1 Minai-Azary Jennifer Lynn · CIK 0001844398 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,010 F1 · price: The price reported above is a weighted average price. These shares were acquired in several transactions at prices ranging from $0.57 - $0.68. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 16:13 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 371,800 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001842952-25-000022 · wk-form4_1739567592.xml · derivative · entry 1 Minai-Azary Jennifer Lynn · CIK 0001844398 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,800 Underlying: Common Stock · 371,800 shares Expires 2035-02-12 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 13, 2026, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 08:04 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 160,115 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001842952-24-000019 · wk-form4_1711109066.xml · derivative · entry 1 Minai-Azary Jennifer Lynn · CIK 0001844398 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,115 Underlying: Common Stock · 160,115 shares Expires 2034-03-20 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on March 21, 2025, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 17:04 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 158,001 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001842952-23-000026 · wf-form4_167641222454214.xml · derivative · entry 1 Minai-Azary Jennifer Lynn · CIK 0001844398 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,001 Underlying: Common Stock · 158,001 shares Expires 2033-02-12 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 13, 2024, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 16:22 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 25,000 | $0.74 | $18,500.00 |
DisclosureSEC source: 0001842952-22-000114 · wf-form4_167148450192465.xml · nonDerivative · entry 1 Minai-Azary Jennifer Lynn · CIK 0001844398 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 17:23 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | PurchaseCommon Stock | 15,000 | $1.80 | $27,000.00 |
DisclosureSEC source: 0001842952-22-000079 · wf-form4_166077142478085.xml · nonDerivative · entry 1 Minai-Azary Jennifer Lynn · CIK 0001844398 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| February 25, 2022 Filed Feb 25, 2022 16:42 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 112,470 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001842952-22-000021 · wf-form4_164582531007999.xml · derivative · entry 1 Minai-Azary Jennifer Lynn · CIK 0001844398 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,470 Underlying: Common Stock · 112,470 shares Expires 2032-02-24 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 25, 2023, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| November 01, 2021 Filed Nov 1, 2021 16:31 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 52,753 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001842952-21-000009 · wf-form4_163579861906118.xml · derivative · entry 1 Minai-Azary Jennifer Lynn · CIK 0001844398 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,753 Underlying: Common Stock · 52,753 shares Expires 2031-11-01 F1 · derivative.exercise_date: The stock option vests each month (1/36 each month) from the date of the grant, November 1, 2021 Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 17:19 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001544227-21-000011 · wf-form4_161472352776309.xml · derivative · entry 1 Minai-Azary Jennifer Lynn · CIK 0001844398 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: 1. Twenty-five percent (25%) of the shares subject to this option shall vest on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.